Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Open access
Taylor, Walter R J, Thriemer, Kamala, von Seidlein, Lorenz, Yuentrakul, Prayoon, Assawariyathipat, Thanawat, Assefa, Ashenafi, Auburn, Sarah, Chand, Krisin, Chau, Nguyen Hoang, Cheah, Phaik Yeong, Dong, Le Thanh, Dhorda, Mehul, Degaga, Tamiru Shibru, Devine, Angela, Ekawati, Lenny L, Fahmi, Fahmi, Hailu, Asrat, Hasanzai, Mohammad Anwar, Hien, Tran Tinh, Khu, Htee, Ley, Benedikt, Lubell, Yoel, Marfurt, Jutta, Mohammad, Hussein, Moore, Kerryn A, Naddim, Mohammad Nader, Pasaribu, Ayodhia Pitaloka, Pasaribu, Syahril, Promnarate, Cholrawee, Rahim, Awab Ghulam, Sirithiranont, Pasathron, Solomon, Hiwot, Sudoyo, Herawati, Sutanto, Inge, Thanh, Ngo Viet, Tuyet-Trinh, Nguyen Thi, Waithira, Naomi, Woyessa, Adugna, Yamin, Fazal Yamin, Dondorp, Arjen, Simpson, Julie A, Baird, J Kevin, White, Nicholas J, Day, Nicholas P, Price, Ric N · 2019 · The Lancet

Abstract

BACKGROUND: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. METHODS: We did a randomised, double-blind, placebo-controlled, non-inferiority trial in eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam). Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled. Patients were given standard blood schizontocidal treatment and randomly assigned (2:2:1) to receive 7 days of supervised primaquine (1·0 mg/kg per day), 14 days of supervised primaquine (0·5 mg/kg per day), or placebo. The primary endpoint was the incidence rate of symptomatic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat population. A margin of 0·07 recurrences per person-year was used to establish non-inferiority of the 7-day regimen compared with the 14-day regimen. This trial is registered at ClinicalTrials.gov (NCT01814683). FINDINGS: Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled. The incidence rate of symptomatic recurrent P vivax malaria was 0·18 (95% CI 0·15 to 0·21) recurrences per person-year for 935 patients in the 7-day primaquine group and 0·16 (0·13 to 0·18) for 937 patients in the 14-day primaquine group, a difference of 0·02 (-0·02 to 0·05, p=0·3405). The incidence rate for 464 patients in the placebo group was 0·96 (95% CI 0·83 to 1·08) recurrences per person-year. Potentially drug-related serious adverse events within 42 days of starting treatment were reported in nine (1·0%) of 935 patients in the 7-day group, one (0·1%) of 937 in the 14-day group and none of 464 in the control arm. Four of the serious adverse events were significant haemolysis (three in the 7-day group and one in the 14-day group). INTERPRETATION: In patients with normal G6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine. The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. FUNDING: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31285-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N. H., Cheah, P. Y., Dong, L. T., Dhorda, M., Degaga, T. S., Devine, A., Ekawati, L. L., Fahmi, F., Hailu, A., Hasanzai, M. A., Hien, T. T., Khu, H., Ley, B., Lubell, Y., Marfurt, J., Mohammad, H., Moore, K. A., Naddim, M. N., Pasaribu, A. P., Pasaribu, S., Promnarate, C., Rahim, A. G., Sirithiranont, P., Solomon, H., Sudoyo, H., Sutanto, I., Thanh, N. V., Tuyet-Trinh, N. T., Waithira, N., Woyessa, A., Yamin, F. Y., Dondorp, A., Simpson, J. A., Baird, J. K., White, N. J., Day, N. P., & Price, R. N.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-09
Volume
394
Issue
10202
Pages
929-938
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2962409343
Cited by
178
References
1
FWCI
17.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31285-1
The paper
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N. H., Cheah, P. Y., Dong, L. T., Dhorda, M., Degaga, T. S., Devine, A., Ekawati, L. L., Fahmi, F., Hailu, A., Hasanzai, M. A., Hien, T. T., . . . Price, R. N. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31285-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.